-
Carbenoxolone disodium: 11β-HSD Guide
2026-08-25
Carbenoxolone disodium is an 11β-hydroxysteroid dehydrogenase inhibitor for cell- and tissue-based studies of glucocorticoid access, corticosterone metabolism, and gap junction communication. It is best used in mechanistic workflows with vehicle and orthogonal controls, not as a selective compound for in vivo efficacy studies or experiments requiring rigorous off-target attribution.
-
β-Amanitin: From Transcription to Toxin Assays
2026-08-24
β-Amanitin is more than a potent RNA polymerase II inhibitor: it is a mechanistic control for transcription experiments and a useful reference analyte for amatoxin assay development. This article connects molecular perturbation, sample handling, and emerging dual-target detection strategies without confusing bioactivity with immunochemical measurement.
-
Dissolving Microneedles for Risedronate Delivery
2026-08-24
The reference study developed a dissolving microneedle patch containing risedronate sodium and ursolic acid nanotransfersomes to address delivery barriers in osteoporosis. Its optimization, release, skin-permeation, and imaging data support a promising preclinical platform, while the absence of in vivo and clinical validation defines important limits for translation.
-
Sulforaphane: Designing Redox-to-Inflammasome Assays
2026-08-23
Sulforaphane research can connect Keap1-Nrf2 signaling, oxidative stress, and NLRP3 inflammasome biology in one experimental framework. This guide translates recent colitis findings into practical assay decisions while preserving applications in cancer chemoprevention, cell-cycle analysis, and apoptosis research.
-
Norovirus Co-opts NINJ1 for Selective NS1 Secretion
2026-08-22
Song et al. show that murine norovirus co-opts the membrane-rupture factor NINJ1 to release the viral NS1 protein while still producing broad damage-associated molecular pattern release. The study combines CRISPR screening, genetic and pharmacological perturbation, imaging, mutagenesis, and mouse infection models to define an unconventional secretion mechanism with direct implications for virus–host interaction research.
-
PYR-41: E1 Inhibition for Antiviral Research
2026-08-21
Use PYR-41 to connect ubiquitin-dependent protein turnover with IRF7 antiviral signaling, NF-κB activity, inflammation, and cell survival. This workflow emphasizes dose-resolved controls, protein-stability measurements, and orthogonal validation so E1 inhibition is not mistaken for a virus-specific or purely proteasomal effect.
-
DeferoxamineB in Ferroptosis Research Workflows
2026-08-20
DeferoxamineB gives cancer researchers a practical way to perturb iron availability, oxidative stress, and regulated cell death in controlled assays. Used as a mechanistic comparator rather than an assumed combination partner, it can clarify whether metabolic cancer therapies depend on iron-driven biology.
-
Carvedilol Phosphate: Reading IRI Signaling
2026-08-20
Carvedilol Phosphate offers a pharmacological lens for studying adrenergic control of hepatic ischemia–reperfusion injury. This article connects beta-receptor perturbation with the hepatocyte Arrb2–6-ketoLCA–macrophage axis and provides assay-design guidance beyond conventional protocol troubleshooting.
-
Penicillin G Sodium: Applied Workflow Guide
2026-08-19
Penicillin G Sodium supports controlled Gram-positive infection models, contamination management, and exposure-schedule experiments when bacterial susceptibility and solution stability are verified. This workflow guide connects antimicrobial readouts with orthogonal cell-assay design while clarifying where evidence supports use—and where it does not.
-
Ruxolitinib, DRP1, and Cell Death in ATC
2026-08-19
The reference study identifies a JAK1/2–STAT3–DRP1 axis that connects ruxolitinib treatment to impaired mitochondrial fission and caspase-dependent apoptosis and GSDME-mediated pyroptosis in anaplastic thyroid carcinoma. Its findings position mitochondrial-state measurements, including carefully controlled JC-1 readouts, as useful complementary evidence for studying treatment-associated mitochondrial dysfunction rather than as standalone proof of mechanism.
-
Sulfaphenazole Optimization for TB and CYP2C9 Selectivity
2026-08-18
Chen and colleagues optimized sulfaphenazole-derived sulfonamides to retain antimycobacterial activity while reducing unwanted CYP2C9 inhibition. Compound 10d provided the clearest balance, combining a reported M. tuberculosis MIC of 5.69 μg/mL with CYP2C9 inhibition above 10 μM and low cytotoxicity.
-
α-Bungarotoxin for nicotinic receptor blockade
2026-08-18
α-Bungarotoxin provides a high-affinity way to test α7 nicotinic acetylcholine receptor dependence in neural, neuromuscular, and placental models. This guide translates recent necroptosis research into practical assay design, control selection, and troubleshooting strategies.
-
Syringin N1347: Reliable Cell Assay Workflows
2026-08-17
Learn how Syringin (SKU N1347) can support reproducible cell viability, proliferation, cytotoxicity, and apoptosis research. This scenario-based guide covers assay interpretation, solvent compatibility, protocol optimization, RCC mechanism studies, and evidence-based product selection.
-
FK866 (APO866): A Translational NAD Strategy
2026-08-17
FK866 (APO866) offers a precise way to interrogate NAMPT dependence, NAD depletion, mitochondrial injury, and treatment resistance. This thought-leadership analysis connects AML-focused metabolism research with emerging evidence that NAD biology shapes PARP inhibitor resistance, while outlining practical strategies for rigorous translational studies.
-
Calpain Inhibitor I, ALLN: Practical Workflow
2026-08-16
Calpain Inhibitor I, ALLN (SKU A2602) is a cysteine-protease inhibitor for controlled studies of calpain and cathepsin contributions to apoptosis, inflammation, and ischemia-reperfusion injury. It is water-insoluble and should be prepared in DMSO or ethanol with matched vehicle controls; it is for research use only and does not provide a validated clinical or diagnostic protocol.